Laboratory Investigation最新文献

{"title":"Clinico-pathological characteristics of a distinct tumor phenotype: invasive lobular carcinoma with tubular elements (ILC-TE) in the WSG ADAPTcycle trial.","authors":"Martin Radner, Sandy Burmeister, Katarzyna Jóźwiak, Nora Schaumann, Malte Gronewold, Mieke Raap, Stephan Bartels, Henriette Christgen, Leonie D Kandt, Pia Hillmann, Ulrich Lehmann, Oleg Gluz, Monika Graeser, Sherko Kümmel, Christine Zu Eulenburg, Nadia Harbeck, Hans Kreipe, Matthias Christgen","doi":"10.1016/j.labinv.2025.104125","DOIUrl":"https://doi.org/10.1016/j.labinv.2025.104125","url":null,"abstract":"<p><strong>Background: </strong>Invasive lobular carcinoma with tubular elements (ILC-TE) is a recently identified variant of invasive lobular breast carcinoma (ILC). The histology of ILC-TE is defined by non-cohesive carcinoma cells mixed with cohesive tubular elements and complete loss of E-cadherin. Cell-cell adhesion is partially restored by switching from an E-cadherin-deficient to a P-cadherin-proficient status (EPS). The prevalence of ILC-TE remains unknown.</p><p><strong>Method: </strong>Here, we report data from the central pathology review of >4.500 hormone receptor-positive/HER2-negative breast cancer (BC) cases recruited to the WSG ADAPTcycle trial (NCT04055493). The central pathology review included prospective assessment of BC types, variants and E-cadherin expression. Cases classified as ILC-TE were analyzed for their molecular features and clinico-pathological characteristics.</p><p><strong>Results: </strong>Pure ILC with complete loss of E-cadherin accounted for 630/4619 (13.6%) BC cases. ILC-TE accounted for 47/630 (7.5%) lobular carcinomas, making it more than twice as prevalent as mixed BC (NST/ILC). ILC-TE harbored deleterious CDH1/E-cadherin mutations in 27/35 (77%) cases tested. EPS was detected in 43/47 (91%) ILC-TE cases. EPS was significantly more common in ILC-TE than in classic ILC or other ILC variants (P<0.001). Clinically, ILC-TE was associated with cT1 stage (P=0.023), cN0 status (P=0.024), lower histologic grade (P=0.004) and lower Ki67 (P=0.012). In contrast, solid ILC was associated with higher Ki67 (P=0.006). Following pre-operative endocrine therapy (pET), higher post-pET Ki67 levels were observed in trabecular ILC, solid-papillary ILC and pleomorphic ILC (P<0.001, P=0.006 and P=0.021).</p><p><strong>Conclusion: </strong>ILC-TE is a quite common ILC variant that is associated with EPS, less aggressive clinical features and slow growth.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104125"},"PeriodicalIF":5.1,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a technique for diagnosis and screening of superficial bladder cancer by cell-pellet DNA from urine sample.","authors":"Jaekwon Seok, Hee Jeong Kwak, Chan-Koo Kang, Ah Ram Kim, Woo Suk Choi, Hyoung Keun Park, Sung Hyun Paick, Hyeong Gon Kim, Yeonjoo Kwak, Tak-Il Jeon, Kyung Min Lim, Baeckseung Lee, Aram Kim, Ssang-Goo Cho","doi":"10.1016/j.labinv.2025.104124","DOIUrl":"https://doi.org/10.1016/j.labinv.2025.104124","url":null,"abstract":"<p><p>Bladder cancer (BCa) is the most common malignancy of the urinary system with high incidence and recurrence rates. There are several ways to detect BCa. However, different approaches have different accuracy, which essentially depends on the sensitivity and specificity of the technique. Alternative non-invasive diagnostic tools for BCa are needed. We isolated and compared urine cell pellet DNA (cpDNA), cell-free DNA, and exosomal DNA from patients with localized BCa. Consequently, we analyzed 12 tissues and cpDNA samples by next-generation sequencing and then used bioinformatic tools to analyze genomic and transcriptomic alterations in coding and non-coding sequences. Then, cpDNA and tissue DNA from 12 patients were analyzed using next-generation sequencing to verify that the genomic characteristics of cpDNA are concordant with those of tissue. We also detected somatic mutation patterns between tissues and their corresponding cpDNA samples. An overlapping variant analysis was performed based on somatic mutation data and observed a high similarity. Moreover, we identified frequently mutated signaling pathways. In these results, several point mutations were analyzed in FGFR3, TTN, and LEPROTL1 from the cpDNA of BCa patients. Tumor mutational burden (TMB) analysis showed cpDNA had no significant difference TMB compared to tumor tissue. These results provide that cpDNA is a potential diagnostic source for detecting and managing bladder cancer using alternative non-invasive methods from patient urine. Our findings may serve as a clinical tool for early detection or recurrence screening of non-muscle invasive BCa using urinary cpDNA.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104124"},"PeriodicalIF":5.1,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation.","authors":"Rui Fang, Tuulia Vallius, Arianna Zhang, Devon Van Cura, Francisco Alicandri, Grant Fischer, Elizabeth Draper, Shuyun Xu, Roxanne Pelletier, Justina Wang, Anna Mandinova, Igor Katsyv, Peter K Sorger, George F Murphy, Christine G Lian","doi":"10.1016/j.labinv.2025.104123","DOIUrl":"10.1016/j.labinv.2025.104123","url":null,"abstract":"<p><p>Preferentially Expressed Antigen in Melanoma (PRAME) and Ten-Eleven Translocation (TET) dioxygenase-mediated 5-hydroxymethylcytosine (5hmC) are emerging melanoma biomarkers. We observed an inverse correlation between PRAME expression and 5hmC levels in benign nevi, melanoma in situ, primary invasive melanoma, and metastatic melanomas via immunohistochemistry and multiplex immunofluorescence: nevi exhibited high 5hmC and low PRAME, whereas melanomas showed the opposite pattern. Single-cell multiplex imaging of melanoma precursors revealed that diminished 5hmC coincides with PRAME upregulation in premalignant cells. Analysis of TCGA and GTEx databases confirmed a negative relationship between TET2 and PRAME mRNA expression in melanoma. Additionally, 5hmC levels were reduced at the PRAME 5' promoter in melanoma compared to nevi, suggesting a role for 5hmC in PRAME transcription. Restoring 5hmC levels via TET2 overexpression notably reduced PRAME expression in melanoma cell lines. These findings establish a function of TET2-mediated DNA hydroxymethylation in regulating PRAME expression and demonstrate epigenetic reprogramming as pivotal in melanoma tumorigenesis.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104123"},"PeriodicalIF":5.1,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AI-assisted detection of breast cancer lymph node metastases in the post-neoadjuvant treatment setting.","authors":"Tony Xu, Dina Bassiouny, Chetan Srinidhi, Michael Sze Wai Lam, Maged Goubran, Sharon Nofech-Mozes, Anne L Martel","doi":"10.1016/j.labinv.2025.104121","DOIUrl":"https://doi.org/10.1016/j.labinv.2025.104121","url":null,"abstract":"<p><p>Lymph node assessment for metastasis is a common, time-consuming, and potentially error prone pathologist task. Past studies have proposed deep learning (DL) algorithms designed to automate this task. However, none have explicitly evaluated the generalizability of these algorithms to lymph nodes in breast cancer patients who have received post-neoadjuvant systemic therapy (NAT). In this study, we create a large, 1027-slide dataset containing exclusively post-NAT breast cancer patients with detailed pathologist labels. We develop an interpretable DL pipeline to carry out two tasks: firstly, to classify slides as positive or negative for metastases, and secondly, to create a detailed, patch-level heatmap for probability of metastasis. We evaluate this pipeline with and without post-NAT treatment effect in training data, and investigate its performance relative to both slide- and patch-level tasks. We find that the presence of post-NAT treatment effect training data is relevant for both tasks, with particular benefits in pipeline specificity. With the post-NAT testing cohort, we found that our final pipeline obtained 0.986 area under the receiver operating characteristic curve (AUC) for slide-level classification, and 70.9% specificity when calibrating for 100% sensitivity. We additionally perform an interpretability study on the outputs of our pipeline, and find that the patch-level heatmap was successful in efficiently guiding pathologists towards detecting and correcting erroneous predictions that were made with an uncalibrated network.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104121"},"PeriodicalIF":5.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “MiR-181b suppresses angiogenesis by directly targeting cellular communication network factor 1” (Lab Invest 2021 Aug;101(8):1026-1035)","authors":"Yue Li ,&nbsp;Siyuan Fan ,&nbsp;Weichang Xia ,&nbsp;Baoru Qiao ,&nbsp;Kai Huang ,&nbsp;Jingqun Zhou ,&nbsp;Minglu Liang","doi":"10.1016/j.labinv.2025.104108","DOIUrl":"10.1016/j.labinv.2025.104108","url":null,"abstract":"","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":"105 4","pages":"Article 104108"},"PeriodicalIF":5.1,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143487581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles for androgen receptor, ADAR2, and PD-L1 in primary urothelial carcinoma in situ of the bladder treated with Bacillus Calmette-Guérin therapy.","authors":"Gabriele Ricciardi, Vincenzo Fiorentino, Francesco Pierconti, Walter Giordano, Emanuela Germanà, Antonio Ieni, Giuseppe Palermo, Marco Racioppi, Marta Rossanese, Vincenzo Ficarra, Cristina Pizzimenti, Giovanni Tuccari, Angela Gallo, Valeriana Cesarini, Guido Fadda, Maurizio Martini","doi":"10.1016/j.labinv.2025.104120","DOIUrl":"https://doi.org/10.1016/j.labinv.2025.104120","url":null,"abstract":"<p><p>In this retrospective observational multicenter study, we identified tumors and immune markers that are related to each other, which could help in selecting bladder primary urothelial carcinoma in situ (CIS) patients who respond better to Bacillus Calmette-Guérin (BCG) therapy. Seventy-three patients with primary bladder CIS who were homogeneously treated with BCG were studied. Tumor-infiltrating lymphocytes (TILs) measured as CD4/CD8 ratio, androgen receptor (AR), ADAR1, ADAR2, and PD-L1 expression were analyzed using immunohistochemistry, whereas miR-200a-3p and INF-γ were evaluated using qPCR on tissues before treatment. Results were correlated with clinicopathological features and Recurrence-Free Survival (RFS). High AR levels in CIS were significantly associated with higher ADAR1 expression, lower ADAR2 expression, higher PD-L1 TPS, higher CD4/CD8 ratio and multifocality of CIS (p<0.001). All patients with the above-mentioned characteristics had significantly worse RFS (p<0.0001). Multivariate and multiple regression analyses confirmed the predictive role of AR, ADAR2, and PD-L1, especially when all three parameters were combined. Additionally, we demonstrated that patients with lower AR and higher ADAR2 expressions had significantly higher levels of miR-200a-3p and INF-γ than those with higher AR and lower ADAR2 expression (p = 0.0011 and p = 0.0002, respectively). Our findings highlight the role of AR in the response to BCG therapy by modulating PD-L1 expression and TILs through the ADAR2, miR-200a-3p, and INF-γ pathways. Furthermore, our data provides valuable insights for optimizing BCG therapy in patients with CIS, paving the way for other possible combined treatment strategies.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104120"},"PeriodicalIF":5.1,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An optimized NGS Protocol for Detecting De Novo MET Amplification in NSCLC: Prognostic and Therapeutic Implications.","authors":"Simon Cabello-Aguilar, Julie A Vendrell, Solène Evrard, Quentin Thomas, Benoît Roch, Frédéric Escudié, Isabelle Solassol, Pierre Brousset, Julien Mazières, Jérôme Solassol","doi":"10.1016/j.labinv.2025.104117","DOIUrl":"https://doi.org/10.1016/j.labinv.2025.104117","url":null,"abstract":"<p><p>MET amplification (MET^amp) is a noteworthy genomic alteration that can occur in patients with non-small cell lung cancer (NSCLC). It has been demonstrated to occur as a primary oncogenic driver that may exist prior to any treatment and is referred to as de novo MET^amp. Despite the recognized significance of this genetic alteration, routine large-scale screening for the early detection of de novo MET^amp is currently lacking in clinical practice and the clinical impact of de novo MET^amp in NSCLC remains poorly investigated. In this study, we developed a NGS-based screening method for detecting and stratifying MET^amp optimized in silico, validated in a patient cohort (n = 72) and applied to 1,932 NSCLC patients. Clinical outcomes (OS and PFS) were assessed in de novo MET^amp cases (n = 46). The optimized NGS-based method achieved high confidence (F-score > 0.99) during in silico optimization. In vivo validation demonstrated high sensitivity (0.93) and specificity (0.97) compared to fluorescent in situ hybridization. de novo MET^amp was found in 2.4% of cases stratified into distinct amplification groups based on the amplification copy number ratio (CNR): Low- (1.5 < CNR ≤ 2.2), Medium- (2.2 < CNR ≤ 4), and High-amplification (CNR > 4). Significant differences in patient outcome (p < 0.001) were observed between the Low- (median OS: 35.9 months), Medium- (median OS: 14.3 months) and High-amplification (median OS: 3.3 months) groups. PFS under chemotherapy was notably reduced in the Medium/High-amplification groups compared to the Low-amplification group (p = 0.001). Screening for MET^amp detection followed by stratification based on MET^amp levels may be considered in all NSCLC patients at diagnosis. This approach could potentially enhance treatment management effectiveness by facilitating inclusion in clinical trials.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104117"},"PeriodicalIF":5.1,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143476815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Utility of Liquid-based Comprehensive Genomic Profiling (CGP) in Gastrointestinal Stromal Tumors (GIST).","authors":"Hiba Mechahougui, Lindsey Hildebrand, James Haberberger, Smruthy Sivakumar, Essia Saiji, Hanna Tukachinsky, Russell Madison, Jonathan K Killian, Richard S P Huang, Julia A Elvin, Eric Marks, Michael C Heinrich, Thibaud Koessler, Douglas I Lin","doi":"10.1016/j.labinv.2025.104116","DOIUrl":"https://doi.org/10.1016/j.labinv.2025.104116","url":null,"abstract":"<p><p>Treatment for GIST focuses on tyrosine kinase inhibitors (TKI), whose selection depends on specific mutations. We sought to determine the clinical utility of liquid biopsy in advanced GIST. Liquid (n=181) (FoundationOne®Liquid CDx) and tissue (n=2,198) (FoundationOne® and FoundationOne®CDx) CGP of GIST were evaluated. The presence of circulating tumor DNA in liquid was determined via tumor fraction (TF), with elevated TF defined as TF ≥1%. Liquid CGP revealed 30% (54/181) of samples had an elevated TF, among which the prevalence of KIT and PDGFRA alterations were 89% (48/54) and 2% (1/54), respectively. In patient-matched tissue/liquid samples (n=49), positive percent agreement of driver alterations in liquid with elevated TF relative to tissue was 100%. 55% (42/77) of liquid samples with a KIT-driver mutation had a co-occurring imatinib-resistant alteration; a minority of cases harbored non-KIT mechanisms of resistance such as FGFR2 fusion, BRAF or EGFR alterations. The relative prevalence of imatinib-resistance KIT exon 13 and 17 mutations was enriched in liquid compared to tissue. Finally, in the liquid cohort, 2.2%, 1.7% and 1.1% of patients were predicted to harbor germline KIT, SDHx, or NF1 mutations, respectively. In conclusion, known driver and TKI-resistant mutations were identified in liquid biopsies of GIST patients with high concordance to tissue in the presence of elevated TF. Liquid biopsy may be valuable in the molecular classification and medical management of GIST.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104116"},"PeriodicalIF":5.1,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143472782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lymphovascular invasion is associated with doxorubicin resistance in breast cancer.","authors":"Allen Joy M Corachea, Regina Joyce E Ferrer, Lance Patrick B Ty, Lizzie Anne Aquino, Madeleine T Morta, Shiela S Macalindong, Gemma Leonora B Uy, Eugene G Odoño, Jo-Hannah S Llames, Francis A Tablizo, Eva Maria C Cutiongco-Dela Paz, Rodney B Dofitas, Michael C Velarde","doi":"10.1016/j.labinv.2025.104115","DOIUrl":"https://doi.org/10.1016/j.labinv.2025.104115","url":null,"abstract":"<p><p>Lymphovascular invasion (LVI), the invasion of tumor within the lymphatic or vascular space, is an early indicator of potential metastasis, with its presence in breast cancer independently predicting poorer outcomes even after neoadjuvant therapy. However, a major limitation is that LVI detection currently relies on post-surgical evaluation. To address this, we determined whether LVI⁺ breast tumors contain a unique gene signature that could facilitate earlier detection. Here, we conducted an integrative analysis of the gene profile between LVI⁺ and LVI^- primary breast tumors from various sources, including published data and our own research, using both microarray and RNA-seq data. Our analysis revealed protein binding and vesicle-related genes to be the most enriched categories in LVI⁺ versus LVI^- tumors. Furthermore, LVI⁺ tumors showed enrichment for xenobiotic metabolism genes, particularly drug metabolism enzymes like cytochrome P450 (CYPs) and UDP glucuronosyltransferases (UGTs). An elastic net regression model containing 13 of these UGT and CYP genes can predict LVI status with 92% accuracy. This suggests a potential link to drug resistance, which was further confirmed by the finding that patients with LVI⁺ tumors had a significantly lower clinical response rate than individuals with LVI^- tumors. We also observed this resistance in patient-derived organoids, with LVI⁺ organoids exhibiting lower sensitivity to doxorubicin, implying that doxorubicin might be less effective for LVI^- breast cancer, potentially contributing to poorer outcomes. Overall, our study unlocked an exciting opportunity for personalized medicine, in that, therapy efficacy and patient outcomes can be improved by incorporating the LVI-associated gene signature into treatment plans.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104115"},"PeriodicalIF":5.1,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selecting a digitization device for bone marrow aspirate smears.","authors":"Farina Kock, Martina Pontones, Tabita Ghete, Markus Metzler, Henning Höfener","doi":"10.1016/j.labinv.2025.104114","DOIUrl":"https://doi.org/10.1016/j.labinv.2025.104114","url":null,"abstract":"<p><p>The digitization of histological specimens has become increasingly common within the last years; however, digitization of cytological slides has its own challenges and there is little guidance on the optimal use of digitization devices for cytopathology. For the morphological analysis of cells in, for example, bone marrow aspirate (BMA) smears, different studies have used a variety of scanner setups and there is no direct comparison between those. This makes it non-trivial to choose an optimal scanner setup. This work pragmatically analyzes different whole slide image (WSI) scanners but also cost-effective light microscope solutions and identifies important aspects for the digitization of cytopathological samples. The aim is to share our experience in selecting a digitization device for generating a BMA dataset.</p>","PeriodicalId":17930,"journal":{"name":"Laboratory Investigation","volume":" ","pages":"104114"},"PeriodicalIF":5.1,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143468381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}